Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 18/20 | 0.45 |
| ▸ | PKD1 | P98161 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26643794 | 1.00 | MAP3K14 (0.45) | MAP3K14PKD1BACE1GRIN1GRIN2A | |
| SCHEMBL29604666 | 0.84 | MAP3K14 (0.48) | MAP3K14PKD1GRIN1GRIN2A | |
| SCHEMBL26643935 | 0.81 | MAP3K14 (0.39) | MAP3K14PKD1BACE1GRIN1GRIN2A | |
| SCHEMBL31691134 | 0.81 | MAP3K14 (0.39) | MAP3K14PKD1BACE1GRIN1GRIN2A | |
| SCHEMBL26644128 | 0.81 | MAP3K14 (0.35) | MAP3K14PKD1GRIN1GRIN2A | |
| SCHEMBL26644140 | 0.81 | MAP3K14 (0.35) | MAP3K14PKD1GRIN1GRIN2A | |
| SCHEMBL29604858 | 0.81 | MAP3K14 (0.39) | MAP3K14BACE1GRIN1GRIN2A | |
| SCHEMBL29604870 | 0.81 | DDB1 (0.34) | MAP3K14PKD1BACE1GRIN1GRIN2A | |
| SCHEMBL26643948 | 0.81 | MAP3K14 (0.40) | MAP3K14PKD1BACE1 | |
| SCHEMBL26643943 | 0.81 | MAP3K14 (0.40) | MAP3K14PKD1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | US | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | MAP3K14 61/4885PKD1 1169/4885BACE1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.